Evidence map›Paper›PMID 20473931›Full record

ArticleInternational journal of cancer2011

A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma.

Myriam Loyo, Mariana Brait, Myoung S Kim, Kimberly L Ostrow, Chunfa C Jie, Alice Y Chuang, Joseph A Califano, Nanette J Liégeois, Shahnaz Begum, William H Westra and 3 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in International journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. PMEnvironmental health and preventive medicine · 2020
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Commented on by
5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Myriam LoyoDepartment of Otolaryngology-Head and Neck Surgery, Greater Baltimore Medical Center, Baltimore, MD 21231, USA.
Mariana Brait
Myoung S Kim
Kimberly L Ostrow
Chunfa C Jie
Alice Y Chuang
Joseph A Califano
Nanette J Liégeois
Shahnaz Begum
William H Westra
Mohammad O Hoque
Qian Tao
David Sidransky
Greater Baltimore Medical Center · USJohns Hopkins University · USChinese University of Hong Kong · CN

Funding

INTEGRATED DEVELOPMENT OF NOVEL MOLECULAR MARKERSU01CA084986 · NCI · JOHNS HOPKINS UNIVERSITY · PI SIDRANSKY, DAVID · 1999 to 2014
$33.8M
TUMOR SUPPRESOR GENE PROMOTER HYPERMETHYLATION FOR DETECTION OF HEAD AND NECKP50DE019032 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI BEDI, ATUL · 2007 to 2016
$27.1M
Tumor Suppressor Gene Promoter Hypermethylation for Detection of Head/Neck CancerP50CA096784 · NCI · JOHNS HOPKINS UNIVERSITY · PI SIDRANSKY, DAVID · 2002 to 2006
$11.3M
MOLECULAR PROGRESSION MODEL FOR HNSCCR01DE012588 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI SIDRANSKY, DAVID · 1998 to 2002
$1.2M
NCI NIH HHS P50 CA096784NCI NIH HHS U01 CA084986NCI NIH HHS U01-CA084986NIDCR NIH HHS P50 DE019032NIDCR NIH HHS P50-DE019032NIDCR NIH HHS R01 DE012588
6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is a rare malignancy with unique genetic, viral and environmental characteristic that distinguishes it from other head and neck carcinomas. The clinical management of NPC remains challenging largely due to the lack of early detection strategies for this tumor. In our study, we have sought to identify novel genes involved in the pathogenesis of NPC that might provide insight into this tumor's biology and could potentially be used as biomarkers. To identify these genes, we studied the epigenetics of NPC by characterizing a panel of methylation markers. Eighteen genes were evaluated by quantitative methylation-specific polymerase chain reaction (PCR) in cell lines as well as in tissue samples including 50 NPC tumors and 28 benign nasopharyngeal biopsies. Significance was evaluated using Fisher's exact test and quantitative values were optimized using cut off values derived from receiver-operator characteristic curves. The methylation status of AIM1, APC, CALCA, deleted in colorectal carcinomas (DCC), DLEC, deleted in liver cancer 1 (DLC1), estrogen receptor alpha (ESR), FHIT, KIF1A and PGP9.5 was significantly associated with NPC compared to controls. The sensitivity of the individual genes ranged from 26 to 66% and the specificity was above 92% for all genes except FHIT. The combination of PGP9.5, KIF1A and DLEC had a sensitivity of 84% and a specificity of 92%. Ectopic expression of DCC and DLC1 lead to decrease in colony formation and invasion properties. Our results indicate that methylation of novel biomarkers in NPC could be used to enhance early detection approaches. Additionally, our functional studies reveal previously unknown tumor suppressor roles in NPC.

Indexed as

Genes, Tumor SuppressorAdolescentAdultAgedBiomarkers, TumorCarcinoma, Squamous CellCase-Control StudiesCell Line, TumorDNA MethylationEpigenesis, GeneticFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGene SilencingHead and Neck NeoplasmsHumansBiomarkers, Tumor

Identifiers

PMID20473931
PMCPMC2955155
OpenAlexW2006883241

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.